Oncotype DX Recurrence Score as an Informative Tool to Optimize Neoadjuvant Therapy in HR-positive, HER2negative Breast Cancers

被引：0
|
作者：
Luzhna, Lidiya
Chia, Stephen
Pauls, Mehrnoosh
Levasseur, Nathalie
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO3-15-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO3-15-04
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Using Oncotype DX Breast Recurrence Score® (RS) assay to define the role of neoadjuvant endocrine therapy (NET) in early-stage hormone receptor positive (HR plus ) breast cancer (BC)
    Taylor, Caitlin
    Foreman, Aimee
    Russell, Christy
    Bandyopdhyay, Dipankar
    Deng, Xiaoyan
    Floyd, Lisa
    Zelnak, Amelia
    O'Regan, Ruth
    Bear, Harry
    Meisel, Jane
    CANCER RESEARCH, 2022, 82 (04)
  • [32] Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer
    Kwon, Mi Jeong
    Lee, Jeong Eon
    Jeong, Joon
    Woo, Sang Uk
    Han, Jinil
    Kang, Byeong-il
    Kim, Jee-Eun
    Moon, Youngho
    Lee, Sae Byul
    Lee, Seonghoon
    Choi, Yoon-La
    Kwon, Youngmi
    Song, Kyoung
    Gong, Gyungyub
    Shin, Young Kee
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [33] Prediction of Oncotype DX recurrence score using deep multi-layer perceptrons in estrogen receptor-positive, HER2-negative breast cancer
    Aline Baltres
    Zeina Al Masry
    Ryad Zemouri
    Severine Valmary-Degano
    Laurent Arnould
    Noureddine Zerhouni
    Christine Devalland
    Breast Cancer, 2020, 27 : 1007 - 1016
  • [34] How we treat HR-positive, HER2-negative early breast cancer
    Lopez-Tarruella, Sara
    Echavarria, Isabel
    Jerez, Yolanda
    Herrero, Blanca
    Gamez, Salvador
    Martin, Miguel
    FUTURE ONCOLOGY, 2022, 18 (08) : 1003 - 1022
  • [35] Change in treatment decisions according to Oncotype Dx Recurrence Score in node positive and negative, estrogen-receptor positive (ER+), HER2 negative breast cancer in a single institution
    Gasol Cudos, A.
    Morales Murillo, S.
    Panades Siurana, M. J.
    Vilardell Villellas, F.
    Canosa Morales, C.
    Mele Olive, J.
    Iglesias Martinez, E.
    Salud Salvia, A.
    BREAST, 2017, 32 : S92 - S93
  • [36] Prediction of Oncotype DX recurrence score using deep multi-layer perceptrons in estrogen receptor-positive, HER2-negative breast cancer
    Baltres, Aline
    Al Masry, Zeina
    Zemouri, Ryad
    Valmary-Degano, Severine
    Arnould, Laurent
    Zerhouni, Noureddine
    Devalland, Christine
    BREAST CANCER, 2020, 27 (05) : 1007 - 1016
  • [37] Routine Use of Oncotype DX Recurrence Score Testing in Node-Positive Hormone Receptor-Positive HER2-Negative Breast Cancer: The Time Has Come
    Elizabeth A. Mittendorf
    Tari A. King
    Annals of Surgical Oncology, 2019, 26 : 1173 - 1175
  • [38] Routine Use of Oncotype DX Recurrence Score Testing in Node-Positive Hormone Receptor-Positive HER2-Negative Breast Cancer: The Time Has Come
    Mittendorf, Elizabeth A.
    King, Tari A.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (05) : 1173 - 1175
  • [39] Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer
    Kim, Esther S.
    Scott, Lesley J.
    TARGETED ONCOLOGY, 2017, 12 (03) : 373 - 383
  • [40] Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer
    Esther S. Kim
    Lesley J. Scott
    Targeted Oncology, 2017, 12 : 373 - 383
12345